Real-World Outcomes of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Obese Patients With Ulcerative Colitis and IPAA With a History of Pouchitis
Our study in a small cohort of patients with UC-IPAA and obesity with a history of pouchitis showed that GLP-1RA use was associated with decreased risk of recurrent pouchitis and anti-diarrheal medication use.
Authors
- Aakash Desai (ORCID: https://orcid.org/0000-0002-6604-7712)
- Francis A. Farraye (ORCID: https://orcid.org/0000-0001-6371-2441)
- Gursimran Kochhar (ORCID: https://orcid.org/0000-0002-0597-2760)
- Edward L. Barnes (ORCID: https://orcid.org/0000-0001-9894-8796)
- Jana G. Hashash (ORCID: https://orcid.org/0000-0001-8305-9742)
- Priya Sehgal (ORCID: https://orcid.org/0000-0003-2611-2767)
- Himsikhar Khataniar
- Hany Habib
Institutions
- University of North Carolina at Chapel Hill (US)
- Allegheny Health Network (US)
- Thomas Jefferson University Hospital (US)
- Jacksonville College (US)
- WinnMed (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1093/ibd/izaf301
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00